HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Siltuximab for multicentric Castleman disease.

Abstract
Dysregulated secretion of IL-6 plays a pivotal role in the pathogenesis of Castleman disease (CD), a rare lymphoproliferative disorder. In contrast to unicentric CD for which surgery is considered the treatment of choice, there is no standard therapeutic approach for multicentric CD (MCD). Siltuximab (trade name: Sylvant, formerly known as CNTO 328) is a chimeric monoclonal antibody with high binding affinity for human IL-6. In a recent randomized placebo-controlled Phase II trial, subjects with HIV-negative, HHV8-negative MCD who received siltuximab demonstrated a significantly higher rate of durable tumor and symptomatic response with a tolerable safety profile, leading to its approval for the treatment of HIV-negative HHV8-negative MCD by the US FDA and the European Commission in April and May 2014, respectively. This article will cover the current treatment options of MCD, the drug profile of siltuximab and future directions in the management of MCD.
AuthorsYi-Chang Liu, Katie Stone, Frits van Rhee
JournalExpert review of hematology (Expert Rev Hematol) Vol. 7 Issue 5 Pg. 545-57 (Oct 2014) ISSN: 1747-4094 [Electronic] England
PMID25110138 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Interleukin-6
  • Receptors, Interleukin-6
  • C-Reactive Protein
  • siltuximab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (adverse effects, pharmacokinetics, therapeutic use)
  • Antineoplastic Agents (adverse effects, pharmacokinetics, therapeutic use)
  • Area Under Curve
  • C-Reactive Protein (analysis)
  • Castleman Disease (drug therapy, pathology)
  • Clinical Trials as Topic
  • Female
  • Half-Life
  • Hematologic Diseases (etiology)
  • Humans
  • Interleukin-6 (antagonists & inhibitors, metabolism)
  • Male
  • Middle Aged
  • Placebo Effect
  • ROC Curve
  • Receptors, Interleukin-6 (chemistry, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: